Why the study?
Therapeutic development for HFpEF has had limited success due to incomplete understanding of its systemic pathophysiology and phenotypic heterogeneity, requiring robust preclinical models that faithfully recapitulate distinct clinical phenogroups.
Design
Review
Authors
Loading...
Diversifying preclinical HFpEF models may better capture clinical heterogeneity; leaves open therapeutic translation pending validation.
Embracing the heterogeneity of HFpEF through diversified preclinical models based on aging, cardiometabolic stress, and chronic hypertension may be key to understanding its pathobiology and developing effective therapeutics.
Roh et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: